B
BEAM
Beam Therapeutics Inc.
25.44
+0.95+3.88%After Hours: 25.80 +0.36 +1.42%16:26 04/08 EDT
OPEN/PREV CLOSE25.92/24.49
TODAY RANGE24.65-26.36
VOL1.85M
MARKET CAP2.59B
52 WEEK RANGE13.53-36.44
AVG VOL (3M)2.01M
% TURNOVER1.81%
TURNOVER--
P/E (TTM)-31.4540
% RANGE6.94%
EPS(TTM)-0.8088
P/E(FORWARD)-5.5097
P/B2.090
BVPS12.17
DIVIDEND--
P/S18.52
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.56B
SHARES OUTSTANDING101.86M
NEXT EARNINGS05/04-05/08
FREE FLOAT100.51M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·2d ago
Why Beam Therapeutics (BEAM) Is Up 12.6% After NEJM Base-Editing Sickle Cell Data Publication
Simply Wall St·4d ago
Assessing Beam Therapeutics (BEAM) Valuation After Major BEACON Trial Milestone For Sickle Cell Therapy
Seeking Alpha·5d ago
Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM
Seeking Alpha·03/31 12:30
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations
Seeking Alpha·03/31 10:35
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
Simply Wall St·03/28 06:11
Beam Therapeutics (BEAM) Is Down 9.9% After Advancing BEAM-302 Into FDA Accelerated Approval Pathway
TipRanks·03/28 04:56
Beam Therapeutics (BEAM) Gets a Buy from Wedbush
Dow Jones·03/26 15:45
Beam Therapeutics Price Target Raised to $68.00/Share From $64.00 by Citigroup
Dow Jones·03/26 15:45
Beam Therapeutics Is Maintained at Buy by Citigroup
Benzinga·03/26 15:35
Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $68
Same Industry
Name/Symbol
Change%
Price